Leflunomide

Across CCLE and GDSC cell-line panels, response to Leflunomide is significantly associated with the protein-level pathway activity of multiple pathways, with BONE cell lines showing a particularly strong set of associations.

The most reproducible Leflunomide response-associated pathways across cancer lineages are mRNA transcription, Cellular response to hydroxyurea, and tRNA decay, each associated with drug response in up to 10 lineages. Since the analysis identifies associations rather than directional relationships, both response-to-biomarker and biomarker-to-response views are provided.

Each biomarker is linked to its corresponding Q-omics profile. The scatter plot shows the strongest observed association, Leflunomide response versus mRNA transcription protein-level pathway activity in BONE (Pearson r = -0.51).

Protein-level pathway activity biomarkers of Leflunomide response

Ranked by combined sampling and lineage consensus. X-score (response→biomarker) and Y-score (biomarker→response) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner pathway	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BONE	mRNA transcription →	-0.242	-0.303	.001	.005	3	10
LARGE_INTESTINE	Cellular response to hydroxyurea →	+0.287	+0.343	.025	.007	3	9
LIVER	tRNA decay →	+1.849	+0.504	.002	.016	3	8
LUNG_NSCLC_LUSC	Negative regulation of protein processing →	-0.483	-0.379	.001	.009	3	8
LARGE_INTESTINE	Free ubiquitin chain polymerization →	+0.962	+0.303	.004	.030	3	8
BONE	Membrane docking →	-0.227	-0.356	<.001	<.001	3	8

Each biomarker links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Leflunomide response vs mRNA transcription — BONE

Explore this scatter interactively →